We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The advocacy group called for the framework to include recommendations from the National Academies of Sciences, Engineering, and Medicines on how to help mitigate the opioid epidemic. Read More
A coalition of unions and advocacy groups is calling on the Federal Trade Commission to investigate AbbVie’s proposed $63 billion acquisition of Allergan for potential anticompetitive behavior — urging it to block the deal if necessary. Read More
Purdue Pharma filed for bankruptcy in the Southern District of New York and confirmed a $10 billion “agreement in principle” for a settlement with 24 states and five U.S. territories over its role in the opioid crisis. Read More
The agency awarded the designation based on clinical data indicating the vaccine may offer substantial improvement compared to the available standard of care. Read More
Because the facility’s reports lacked key information, the agency was only able to link a small percentage of the adverse events to the use of compounded hormone pellets containing testosterone. Read More
The Drug Enforcement Administration (DEA) has recommended that production of five prominent opioids should be cut significantly next year to lower risks of diversion and misuse. Read More
The U.S. Patent Trial and Appeals Board (PTAB) has agreed to conduct an inter partes review of two of Amgen’s patents on the chemotherapy drug Neupogen (filgrastim). Read More
CDER Director Janet Woodcock announced Friday that the FDA is investigating an impurity in certain heartburn drugs previously found in blood pressure drugs. Read More